The U.S. FDA has approved the second non-prescription opioid overdose reversal drug called "RiVive," a nasal spray version of naloxone.

The U.S. Food and Drug Administration has approved the prescription-free sale of the second opioid overdose reversal drug, its manufacturer Harm Reduction Therapeutics said on Friday.